Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
3D Culture/Scaffold

Stem Cell Related Patent Number US5486359

Title:Human mesenchymal stem cells
Inventors:Caplan, Arnold I.; Cleveland Heights, OH, USA
Haynesworth, Stephen E.; Cleveland Heights, OH, USA
Summary:Described herein are isolated human mesenchymal stem cells (hMSCs), methods and uses thereof. The invention relates to hMSCs which can differentiate into cells of more than one connective tissue type such as bone, cartilage, muscle or marrow stroma. Further disclosed are methods for the isolation, purification and cultural expansion without differentiation of the hMSCs. Also provided are monoclonal antibodies specific for hMSCs and the monoclonal hybridoma cell lines identified by ATCC nos. 10743-10745 which synthesize and secrete these monospecific antibodies. Therapeutic and diagnostic applications are included for the regeneration of mesenchymal cells in vivo and for the production of mesenchymal tissue in vitro.
Abstract:Isolated human mesenchymal stem cells which can differentiate into more than one tissue type (e.g. bone, cartilage, muscle or marrow stroma), a method for isolating, purifying, and culturally expanding human mesenchymal stem cells (i.e. mesenchymal stem cells or hMSCs), and characterization of and uses, particularly research reagent, diagnostic and therapeutic uses for such cells. The stem cells can be culture expanded without differentiating. Monoclonal antibodies specific for human mesenchymal stem cells and the monoclonal hybridoma cell lines (ATCC nos. 10743-10745) that synthesize and secrete these monospecific antibodies, and uses of the monoclonal antibodies for diagnostic and/or therapeutic purposes.
US Patent Website:Click Here for Full Text of Patent
Title Number:US5486359
Application Number:US1994000193262
Date Filed:08/02/1994
Date Published:23/01/1996
Assignee:Osiris Therapeutics, Inc., Cleveland, OH, USA

Copyright © 2007 The Institute for Cellular Medicine  10/5/2022